Home/Pipeline/Klisyri (tirbanibulin)

Klisyri (tirbanibulin)

Actinic Keratosis

MarketedCommercial GrowthNCT03285477

Key Facts

Indication
Actinic Keratosis
Phase
Marketed
Status
Commercial Growth
Company

About Almirall

Almirall is a publicly traded, revenue-generating pharmaceutical company with a singular strategic focus on becoming a global leader in medical dermatology. The company has successfully transformed from a broad-based pharma player into a specialized dermatology entity, leveraging deep internal R&D, strategic partnerships, and a direct commercial infrastructure. Its mission is to deliver innovative science to improve the lives of patients with skin conditions, supported by a growing portfolio of marketed products and a promising clinical pipeline.

View full company profile

Other Actinic Keratosis Drugs

DrugCompanyPhase
15dPMJ2Claradele PharmaceuticalsPre-clinical
Skinject PatchSkinjectResearch
Bimiralisib (PQR309)TorqurPhase 2
RLS-1496Rubedo Life SciencesPhase 1
VD-001Vidac PharmaPhase 2B